Menogaril (BioDeep_00000668698)

   


代谢物信息卡片


2,6-Epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione,4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-,(2R,3S,4R,5R,6R,11R,13R)-

化学式: C28H31NO10 (541.1947866)
中文名称: 美诺立尔
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1(CC(C2=C(C3=C(C=C2C1)C(=O)C4=C5C(=CC(=C4C3=O)O)C6(C(C(C(C(O5)O6)O)N(C)C)O)C)O)OC)O
InChI: InChI=1S/C28H31NO10/c1-27(36)8-10-6-11-16(21(32)15(10)14(9-27)37-5)22(33)17-13(30)7-12-24(18(17)20(11)31)38-26-23(34)19(29(3)4)25(35)28(12,2)39-26/h6-7,14,19,23,25-26,30,32,34-36H,8-9H2,1-5H3/t14-,19+,23+,25-,26-,27-,28-/m1/s1

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D000970 - Antineoplastic Agents

同义名列表

3 个代谢物同义名

2,6-Epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione,4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-,(2R,3S,4R,5R,6R,11R,13R)-; Menogaril; Menogarol



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • T Taguchi, A Wakui, H Niitani, H Furue, H Majima, I Nakao, K Ota, T Hattori, K Sugimachi. [TUT-7 phase I clinical study. TUT-7 Study Group]. Gan to kagaku ryoho. Cancer & chemotherapy. 1997 Jul; 24(9):1125-33. doi: NULL. [PMID: 9239166]
  • G Falkson, S Lipsitz, E Borden, I Simson, D Haller. Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril. American journal of clinical oncology. 1995 Aug; 18(4):287-92. doi: NULL. [PMID: 7625367]
  • A A Piergies, A B Benson. Pharmacokinetics and acute cardiovascular effects of menogaril in patients with metastatic tumors. International journal of clinical pharmacology and therapeutics. 1995 Feb; 33(2):63-9. doi: NULL. [PMID: 7757312]
  • G R Weiss, T D Brown, J G Kuhn, D D Von Hoff, R H Earhart, W J Adams, J E Brewer, J D Hosley, D A Kasunic. A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril. Investigational new drugs. 1993 Feb; 11(1):17-27. doi: 10.1007/bf00873906. [PMID: 8349432]
  • D J Stewart, D Grewaal, R M Green, R Goel, N Mikhael, V A Montpetit, D Redmond, R Earhart. Human autopsy-tissue distribution of menogaril and its metabolites. Cancer chemotherapy and pharmacology. 1993; 32(5):373-8. doi: 10.1007/bf00735922. [PMID: 8339388]
  • K Ohashi, H Hara, F Takahashi, R Aso, T Akimoto, K Nakama. [Pharmacokinetic studies of menogaril (TUT-7) with rats]. Gan to kagaku ryoho. Cancer & chemotherapy. 1992 Sep; 19(11):1825-9. doi: NULL. [PMID: 1387773]
  • H J Long, M D Hauge, T M Therneau, J C Buckner, S Frytak, R G Hahn. Phase II evaluation of menogaril in patients with advanced hypernephroma. Investigational new drugs. 1991 Aug; 9(3):261-2. doi: 10.1007/bf00176980. [PMID: 1838363]
  • B A Conley, M J Egorin, V Sinibaldi, D A Van Echo. Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function. Investigational new drugs. 1990 Nov; 8(4):365-7. doi: 10.1007/bf00198592. [PMID: 2150671]
  • R L Stephens, P Goodman, E D Crawford, C F Spicer, B A Lowe, F R Ahmann, R Chapman, R B Natale. Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504). Investigational new drugs. 1990; 8 Suppl 1(?):S69-71. doi: 10.1007/bf00171987. [PMID: 2143177]
  • W J Adams, J P McGovren, E A Dalm, J E Brewer, J D Hosley. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. Cancer research. 1989 Nov; 49(22):6328-36. doi: NULL. [PMID: 2529962]
  • P Dodion, D de Valeriola, N Crespeigne, B Peeters, F Wery, C van Berchem, M Piccart, E Tueni, J Joggi, Y Kenis. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days. European journal of cancer & clinical oncology. 1988 Jun; 24(6):1019-26. doi: 10.1016/0277-5379(88)90152-6. [PMID: 2970391]
  • M J Egorin, B A Conley, A Forrest, E G Zuhowski, V Sinibaldi, D A Van Echo. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. Cancer research. 1987 Nov; 47(22):6104-10. doi: NULL. [PMID: 2959359]
  • H J Long, G Powis, A J Schutt, C G Moertel. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion. Cancer treatment reports. 1987 Jun; 71(6):593-8. doi: NULL. [PMID: 2953414]
  • M L Zanette, U Tirelli, R Sorio, D Zadro, F Figoli, S Monfardini, M D'Incalci. Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors. Cancer chemotherapy and pharmacology. 1987; 20(1):67-70. doi: 10.1007/bf00252962. [PMID: 2957106]
  • S Wadler, J Z Fuks, P H Wiernik. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. Journal of clinical pharmacology. 1986 Sep; 26(7):491-509. doi: 10.1002/j.1552-4604.1986.tb02942.x. [PMID: 2944917]
  • P Dodion, C Sessa, R Joss, N Crespeigne, Y Willems, M Kitt, J Abrams, C Finet, J E Brewer, W J Adams. Phase I study of intravenous menogaril administered intermittently. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1986 May; 4(5):767-74. doi: 10.1200/jco.1986.4.5.767. [PMID: 2939203]
  • M J Egorin, D A Van Echo, M Y Whitacre, A Forrest, L M Sigman, K L Engisch, J Aisner. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer research. 1986 Mar; 46(3):1513-20. doi: NULL. [PMID: 2935249]
  • P Dodion, M J Egorin, K L Engisch, N R Bachur. Metabolism and disposition of menogaril (NSC 269148) in the rabbit. Cancer research. 1985 Nov; 45(11 Pt 1):5352-7. doi: NULL. [PMID: 2932217]
  • J P McGovren, R D Hamilton, W J Adams, E A Pratt. Quantitation of anthracycline antitumor agent menogarol in plasma using liquid chromatography with fluorescence detection. Analytical chemistry. 1984 Aug; 56(9):1587-90. doi: 10.1021/ac00273a011. [PMID: 6237597]
  • P Dodion, B K Chang, M J Egorin, E A Olman, K L Engisch, N R Bachur. The disposition of the new anthracycline antibiotic, menogarol, in mice. Drug metabolism and disposition: the biological fate of chemicals. 1984 May; 12(3):365-70. doi: NULL. [PMID: 6145565]
  • J P McGovren, K G Nelson, M Lassus, J C Cradock, J Plowman, J P Christopher. Menogaril: a new anthracycline agent entering clinical trials. Investigational new drugs. 1984; 2(4):359-67. doi: 10.1007/bf00171586. [PMID: 6239835]
  • J E Brown, P A Wilkinson, J R Brown. Rapid high-performance liquid chromatographic assay for the anthracyclines daunorubicin and 7-con-O-methylnogarol in plasma. Journal of chromatography. 1981 Dec; 226(2):521-5. doi: 10.1016/s0378-4347(00)86092-2. [PMID: 6459335]